Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.16, read 2026-10-27
Ethical passes the values gate
Price69.57 USD
Fair value96.00
Ethical score82.8/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-10-11Read Accumulation66.78+4.2% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown66.78+4.2% to today Accumulation gives way to Markdown after an 11% slide in 5 weeks
2026-08-30Read Accumulation74.82-7.0% to today Distribution gives way to Accumulation after a 16% rise in 8 weeks
2026-07-02Read Distribution64.67+7.6% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
GE HealthCare holds its Accumulation at $69.57. Consolidating, no directional conviction, held for 41 days.
As held on the ledger · 2026-10-16
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 41 days
Price at the screen
$69.57
Valuation
15.99 trailing · 12.86 forward price to earnings
Values screen
PASS· score 82.8
Beta
0.85
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.35%
Below 33%
Interest-bearing debt is just 28.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.95%
Below 33%
Cash held in interest-bearing accounts and securities is 1.0% of assets, under the one-third limit.
Pass
Receivables
22.25%
Below 49%
Money owed to the company is 22.2% of assets, under the 49% limit.
Pass
Revenue purity
0.20%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
GE HealthCare clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when GEHC's ethical verdict changes
Today GEHC passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads OPPORTUNITY: it trades at roughly a 38% discount to our $96.00 fair value, narrow competitive moat, 5.80% revenue growth.
Fair value range in USD, drawn from the 2026-10-16 screen. The gold marker is the market price at the same screen. A 38.0% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus Buy. The average target sits +21% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-16 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Hospitals rely on kit that rarely fails
Walk into any busy imaging suite and the scanners and monitors keeping patients safe often trace back to established medical device makers. GE HealthCare stands out here because it combines 7% revenue growth, a 19% return on equity and a forward earnings multiple of just 11.8 times, all while clearing the ethical screen and offering a 55% margin of safety to our fair value.
The narrow moat and 9% profit margin reflect steady but not explosive demand for diagnostic and monitoring gear worldwide. Eighteen analysts see further upside with a median target of 80 dollars, yet the real attraction is the cash generation and pricing power that still sits below what the market normally awards similar healthcare compounders.
Risk sits mainly in hospital capital budgets that can tighten quickly during funding squeezes, plus competition that keeps the moat from widening. Currency moves and supply chain hiccups add further volatility. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GEHC trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-27Accumulation$69.57+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$69.57+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$69.57+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$69.57+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$69.57+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Accumulation$69.57+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$69.57+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Accumulation$69.57+4.2%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80.
2026-10-02Markdown · changed$66.78-10.7%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
